NCT07570017

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2026-06-25Est. Completion: 2027-12-31

Enrollment target: 42 participants

Locations

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China

Contact

Qingqing Caicaiqq@sysucc.org.cn 086-20-87343355

Rong Taohkutao@hotmail.com 086-210-64175590

Other microbiome trials you might be interested in

Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyPhase 2Recruiting

Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Refractory Large B-cell Lymphoma (LBCL)Refractory T-cell/Histiocyte-rich Large B-cell LymphomaRefractory Transformed Follicular LymphomaRefractory High-Grade B-Cell LymphomaRefractory Follicular Lymphoma Grade 3B

The goal of this Phase 2, open-label, multicenter clinical trial is to assess the efficacy and safety of accelerated ram…

Créteil, FranceEst. completion Jul 2028

View Trial →

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaPhase 2Recruiting

High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.